Immunosuppressive
PreclinicalSmall molecule
Chiesi Farmaceutici S.p.A.Immunosuppressive is one of 126 small molecule programs targeting Metabolic Syndrome. It is currently in Preclinical.
3
Indications
3
Total Trials
0
Active Trials
125
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
317 competitors in COVID-19
#DrugCompanyPhaseTrials
1Stivarga
BayerPreclinical
Aimovig
AmgenPreclinical
Aldactone
PfizerPreclinical
Nexavar
BayerPreclinical
Calciferol
Jazz PharmaceuticalsPreclinical
Activella
Eli LillyPreclinical
Angiomax
BBaxter Healthcare Corporation
Preclinical
Tricor
JJagotec
Preclinical
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Benadryl
PParkedale
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Kidney Transplant1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Immunosuppressive. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company